Please use this identifier to cite or link to this item:
Title: Determinants of licensing A study of selected biotech companies and research institutions
Researcher: Binu, Thomas
Guide(s): Chugan, P K
Keywords: Biotech
Business Finance
Economics and Business
Social Sciences
University: Nirma University
Completed Date: 2020
Abstract: Licensing and collaborations are very important for the pharmaceutical and biotech institutes to discover, develop, manufacture and commercialize new medicines for treatment of human diseases. With the advancement in science and technology, our understanding of human biology, drug targets and mechanisms of drug resistance have increased manifold. However, it takes several years and billions of dollars in investment to bring a new drug to the marketplace. The period for new product discovery, development and eventual approval for marketing is the longest in the case of pharmaceutical industry leading to loss of effective on-market patent life of a new molecule. This coupled with the high risk of failure in clinical development makes it important for pharmaceutical companies to seek external innovation to fill their portfolio. newlineBiotech s that have achieved non-clinical or clinical proof-of-concept need the access to capital to conduct expensive phases of non-clinical and clinical drug development. The licensing process can be very competitive as there would be several pharmaceutical companies interested in licensing first-in-class or best-in-class molecules at various stages of development. However, it is important for biotech and pharmaceutical companies that are seeking licensing partners for their molecules to choose the partners carefully as it takes several years of commitment to bring a new drug to the market. This study investigated the literature on different aspects of new drug discovery and development and the need for licensing by pharmaceutical companies seeking access to new drugs to fill their product portfolios. The study laid special emphasis on licensing in the global context as well as licensing activities by Indian pharmaceutical and biotech companies. newlineThis study investigated the five determinants including size of the company, pharmaceutical sales, number of employees, age of the company and pharmaceutical research and development expenditure as key determinants that could have an effe
Appears in Departments:Institute of Management

Files in This Item:
File Description SizeFormat 
01_title.pdfAttached File96.32 kBAdobe PDFView/Open
02_certificate.pdf52.69 kBAdobe PDFView/Open
03_abstract.pdf291.9 kBAdobe PDFView/Open
04_declaration.pdf56.15 kBAdobe PDFView/Open
05_acknowledgement.pdf180.7 kBAdobe PDFView/Open
06_contents.pdf189.97 kBAdobe PDFView/Open
07_list_of_tables.pdf195.43 kBAdobe PDFView/Open
08_list_of_figures.pdf287.33 kBAdobe PDFView/Open
09_abbreviations.pdf294.6 kBAdobe PDFView/Open
10_chapter_1.pdf745.47 kBAdobe PDFView/Open
11_chapter_2.pdf1.15 MBAdobe PDFView/Open
12_chapter_3.pdf484.48 kBAdobe PDFView/Open
13_chapter_4.pdf748.49 kBAdobe PDFView/Open
14_chapter_5.pdf383.31 kBAdobe PDFView/Open
15_chapter_6.pdf318.51 kBAdobe PDFView/Open
16_chapter_7.pdf285.56 kBAdobe PDFView/Open
17_chapter_8.pdf297.73 kBAdobe PDFView/Open
18_conclusion.pdf289.89 kBAdobe PDFView/Open
19_bibilography.pdf500.91 kBAdobe PDFView/Open
80_recommendation.pdf477.42 kBAdobe PDFView/Open
Show full item record

Items in Shodhganga are licensed under Creative Commons Licence Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0).

Altmetric Badge: